Alnylam Pharmaceuticals (AgeTech UK) Covid-19

Covid-relevant. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished scientific leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics – ONPATTRO (patisiran) in 2018 and GIVLAARI® (givosiran) in 2019. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Investors

Connections from

Funding Status: N/A
Headquarters: United Kingdom
Founded Date: N/A
Investor Type: N/A
Investment Stage: N/A
Technology: AgeTech Companies
Employee Number: N/A
Number Of Exists: N/A
Industry: UK AgeTech 2020
N/A
Register and Claim Ownership